Adjuvant Therapy for High-Risk Breast Cancer With Wkly Adriamycin & Oral Cytoxan With G-CSF for 12 Wks; Wkly Taxol x 12
Status:
Completed
Trial end date:
2011-03-01
Target enrollment:
Participant gender:
Summary
The primary objectives of the study are to evaluate the feasibility and toxicity of treatment
with 12 weeks of Adriamycin with daily oral Cytoxan with G-CSF support followed by 12 weeks
of Taxol. Feasibility will be assessed by comparing the delivered dose intensity of each drug
to the delivered dose intensity in previous trials. Toxicity will be assessed by comparing
the incidence and severity of toxicity with these drugs to previous trials using these drugs
in the same combination. We hypothesize metronomic, dose dense treatment as given in this
study will be less toxic and more effective than historical regimens using the same drugs in
a less metronomic, dose dense manner.